Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
100
Frequently Asked Questions
What is Market Cap of MoonLake Immunotherapeutics - Ordinary Shares - Class A?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. MoonLake Immunotherapeutics - Ordinary Shares - Class A market cap is $3.45B.
What is the 52-week high for MoonLake Immunotherapeutics - Ordinary Shares - Class A?
52 week high is the highest price of a stock in the past 52 weeks, or one year. MoonLake Immunotherapeutics - Ordinary Shares - Class A 52 week high is $61.87 as of September 13, 2025.
What is the 52-week low for MoonLake Immunotherapeutics - Ordinary Shares - Class A?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. MoonLake Immunotherapeutics - Ordinary Shares - Class A 52 week low is $31.42 as of September 13, 2025.
What is MoonLake Immunotherapeutics - Ordinary Shares - Class A stock price today?
MoonLake Immunotherapeutics - Ordinary Shares - Class A stock price today is $52.62.
What was MoonLake Immunotherapeutics - Ordinary Shares - Class A stock price yesterday?
MoonLake Immunotherapeutics - Ordinary Shares - Class A stock price yesterday was $54.30.
What is the PE ratio of MoonLake Immunotherapeutics - Ordinary Shares - Class A?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. MoonLake Immunotherapeutics - Ordinary Shares - Class A’s P/E ratio is -19.46.
What is the Price-to-Book ratio of MoonLake Immunotherapeutics - Ordinary Shares - Class A?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. MoonLake Immunotherapeutics - Ordinary Shares - Class A P/B ratio is 9.7437.
What is the 50-day moving average of MoonLake Immunotherapeutics - Ordinary Shares - Class A?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. MoonLake Immunotherapeutics - Ordinary Shares - Class A 50-day moving average is $53.55.
How many employess does MoonLake Immunotherapeutics - Ordinary Shares - Class A has?
MoonLake Immunotherapeutics - Ordinary Shares - Class A has 100 employees.
